Thanh Hung Nguyen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Thanh Hung Nguyen has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Bishwanath Chatterjee
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
10 shared publications - Frederic G. Barr
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892
10 shared publications - Hana Kim
National Cancer Institute 1 Laboratory of Pathology, Center for Cancer Research Bethesda, Maryland
10 shared publications - Pawan Kumar Raut
National Cancer Institute 1 Laboratory of Pathology, Center for Cancer Research Bethesda, Maryland
10 shared publications - Puspa Raj Pandey
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
10 shared publications - Reyaz Ur Rasool
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
10 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (1) , e327626
Platelet-Targeted Self-Amplifying mRNA for Safe, Long-Acting Thromboprophylaxis
BACKGROUND: Thrombosis is a major contributor to morbidity and mortality in cardiovascular diseases. Although current antiplatelet therapies reduce thrombotic complications, they are associated with systemic bleeding complications. We previously developed a single-chain variable fragment (scFv) that specifically binds and blocks the activated platelet integrin αIIbβ3 (GPIIb/IIIa [glycoprotein IIb/IIIa]), preventing thrombosis without impairing hemostasis. We hypothesized that an mRNA-based therapeutic encoding scFv αIIbβ3 would offer prolonged expression and enhanced therapeutic durability while maintaining a favorable safety profile. METHODS: We designed and synthesized both conventional mRNA and self-amplifying mRNA constructs encoding scFv αIIbβ3 . The constructs were first validated in vitro by confirming their expression of a functional scFv αIIbβ3 . For in vivo experiments, mRNAs were encapsulated in a novel lipid nanoparticle formulation comprising of γ-oryzanol and DLin-KC2-DMA (OryKL) for systemic delivery. Their biosafety was assessed by a series of biochemical and histological examinations. The murine FeCl 3 -induced arterial thrombosis model was used to assess the preventive effect of scFv αIIbβ3 -encoding mRNAs on thrombus formation. RESULTS: In vitro assays confirmed the efficient expression and secretion of a functional scFv αIIbβ3 that selectively bound to and blocked activated GPIIb/IIIa, thereby inhibited platelet aggregation. In mice with induced thrombosis, OryKL-delivered scFv αIIbβ3 mRNA significantly prolonged occlusion time at 24 hours posttreatment, while self-amplifying mRNA provided sustained thromboprotection for over 7 days. Tail bleeding times were unchanged across all groups, and no systemic toxicity or histopathologic abnormalities were observed. CONCLUSIONS: Our findings demonstrate that scFv αIIbβ3 mRNA and self-amplifying mRNA therapeutics enable safe, effective, and long-acting antithrombotic protection in vivo, offering a promising strategy for thromboprophylaxis that prevents the bleeding risks associated with current antiplatelet therapies.
- 19 June 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (1) , e327626
Open AccessPlatelet-Targeted Self-Amplifying mRNA for Safe, Long-Acting Thromboprophylaxis
BACKGROUND: Thrombosis is a major contributor to morbidity and mortality in cardiovascular diseases. Although current antiplatelet therapies reduce thrombotic complications, they are associated with systemic bleeding complications. We previously developed a single-chain variable fragment (scFv) that specifically binds and blocks the activated platelet integrin αIIbβ3 (GPIIb/IIIa [glycoprotein IIb/IIIa]), preventing thrombosis without impairing hemostasis. We hypothesized that an mRNA-based therapeutic encoding scFv αIIbβ3 would offer prolonged expression and enhanced therapeutic durability while maintaining a favorable safety profile. METHODS: We designed and synthesized both conventional mRNA and self-amplifying mRNA constructs encoding scFv αIIbβ3 . The constructs were first validated in vitro by confirming their expression of a functional scFv αIIbβ3 . For in vivo experiments, mRNAs were encapsulated in a novel lipid nanoparticle formulation comprising of γ-oryzanol and DLin-KC2-DMA (OryKL) for systemic delivery. Their biosafety was assessed by a series of biochemical and histological examinations. The murine FeCl 3 -induced arterial thrombosis model was used to assess the preventive effect of scFv αIIbβ3 -encoding mRNAs on thrombus formation. RESULTS: In vitro assays confirmed the efficient expression and secretion of a functional scFv αIIbβ3 that selectively bound to and blocked activated GPIIb/IIIa, thereby inhibited platelet aggregation. In mice with induced thrombosis, OryKL-delivered scFv αIIbβ3 mRNA significantly prolonged occlusion time at 24 hours posttreatment, while self-amplifying mRNA provided sustained thromboprotection for over 7 days. Tail bleeding times were unchanged across all groups, and no systemic toxicity or histopathologic abnormalities were observed. CONCLUSIONS: Our findings demonstrate that scFv αIIbβ3 mRNA and self-amplifying mRNA therapeutics enable safe, effective, and long-acting antithrombotic protection in vivo, offering a promising strategy for thromboprophylaxis that prevents the bleeding risks associated with current antiplatelet therapies.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Supplementary Table 1 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Supplementary Table 1 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Effect of FGF8 on FGFR4 expression in human myoblast cell lines
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Effect of FGF8 on FGFR4 expression in human myoblast cell lines
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Supplementary Table 2 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Supplementary Table 2 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Effect of FGFR inhibitors on colony growth of FP-RMS cells
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Effect of FGFR inhibitors on colony growth of FP-RMS cells
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Gene reporter assay investigating the regulatory effect of the LTR
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Gene reporter assay investigating the regulatory effect of the LTR
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Effect of high FGF8 expression on P3F-induced expression of FGFR4
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Effect of high FGF8 expression on P3F-induced expression of FGFR4
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Expression of FGFs and FGFRs in RMS tumors
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Expression of FGFs and FGFRs in RMS tumors
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
We previously used a myoblast model of fusion-positive rhabdomyosarcoma (FP-RMS) to show that FGF8, a PAX3–FOXO1 (P3F) transcriptional target, is required for P3F-driven tumorigenicity and, when aberrantly expressed, can maintain tumorigenicity in P3F-independent recurrent tumors. We report in this study that FGF8, FGFR1, and FGFR4 are often highly expressed in FP-RMS tumors. High FGF8 expression in FP-RMS cells is associated with high sensitivity to an FGFR4 inhibitor and a pan-FGFR inhibitor. Although downregulating FGF8 resulted in loss of sensitivity to these inhibitors, FGF8 upregulation in myoblasts decreased FGFR4 expression and sensitized the cells to an FGFR1 inhibitor and a pan-FGFR inhibitor. FGF8 downregulation of FGFR4 expression was reverted by inhibitors of FGFR1, MEK, or ERK, thus defining a signaling pathway by which FGF8 mediates this regulatory effect. Finally, high FGF8 expression in P3F-independent recurrent tumors was attributable to a rearrangement of viral long terminal repeat (LTR) sequences into the FGF8 3′ untranslated region, resulting in increased FGF8 mRNA stability. These findings indicate that FGF8 exerts oncogenic effects in FP-RMS via FGFR4 and may exert oncogenic effects in P3F-independent relapses via FGFR1. Our study reveals the functional significance of FGF8 in FP-RMS and provides a rationale for preclinical studies of FGFR inhibitors in FP-RMS.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
We previously used a myoblast model of fusion-positive rhabdomyosarcoma (FP-RMS) to show that FGF8, a PAX3–FOXO1 (P3F) transcriptional target, is required for P3F-driven tumorigenicity and, when aberrantly expressed, can maintain tumorigenicity in P3F-independent recurrent tumors. We report in this study that FGF8, FGFR1, and FGFR4 are often highly expressed in FP-RMS tumors. High FGF8 expression in FP-RMS cells is associated with high sensitivity to an FGFR4 inhibitor and a pan-FGFR inhibitor. Although downregulating FGF8 resulted in loss of sensitivity to these inhibitors, FGF8 upregulation in myoblasts decreased FGFR4 expression and sensitized the cells to an FGFR1 inhibitor and a pan-FGFR inhibitor. FGF8 downregulation of FGFR4 expression was reverted by inhibitors of FGFR1, MEK, or ERK, thus defining a signaling pathway by which FGF8 mediates this regulatory effect. Finally, high FGF8 expression in P3F-independent recurrent tumors was attributable to a rearrangement of viral long terminal repeat (LTR) sequences into the FGF8 3′ untranslated region, resulting in increased FGF8 mRNA stability. These findings indicate that FGF8 exerts oncogenic effects in FP-RMS via FGFR4 and may exert oncogenic effects in P3F-independent relapses via FGFR1. Our study reveals the functional significance of FGF8 in FP-RMS and provides a rationale for preclinical studies of FGFR inhibitors in FP-RMS.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
RNA expression in engineered FP-RMS cells and myoblast lines
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
RNA expression in engineered FP-RMS cells and myoblast lines